Common name
N,N-dimethylformamide
IUPAC name
N,N-dimethylformamide
SMILES
O=CN(C)C
Common name
N,N-dimethylformamide
IUPAC name
N,N-dimethylformamide
SMILES
O=CN(C)C
INCHI
InChI=1S/C3H7NO/c1-4(2)3-5/h3H,1-2H3
FORMULA
C3H7NO
Common name
N,N-dimethylformamide
IUPAC name
N,N-dimethylformamide
Molecular weight
73.094
clogP
-0.682
clogS
0.197
Frequency
0.0041
HBond Acceptor
1
HBond Donor
0
Total PolarSurface Area
20.31
Number of Rings
0
Rotatable Bond
1
| Drug ID | Common name | Structure CAS | Compound class | Therapeutic area |
|---|---|---|---|---|
| FDBD00302 | Zolpidem |
|
Hypnotics and Sedatives; GABA-A Receptor Agonists; Nervous System; Psycholeptics; Benzodiazepine Related Drugs; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C19 Inducers; CYP2D6 Inducers; CYP2D6 Inducers (strong); CYP3A4 Inhibitors; | For the short-term treatment of insomnia. |
| FDBD00624 | Meropenem |
|
Anti-Bacterial Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Carbapenems; | For use as single agent therapy for the treatment of the following infections when caused by susceptible isolates of the designated microorganisms: . |
| FDBD00698 | Loperamide |
|
Antidiarrheals; Alimentary Tract and Metabolism; Antidiarrheals, Intestinal Anti-Inflammatory/antiinfective Agents; Antipropulsives; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inhibitors; CYP2B6 Inhibitors (strong); CYP2D6 Inducers; CYP2D6 Inducers (strong); CYP3A4 Inhibitors; | For the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease or gastroenteritis. Also used for reducing the volume of discharge from ileostomies. |
| FDBD01659 | Edoxaban |
|
Factor Xa Inhibitors; | Edoxaban is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). However, it should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg). It is also indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant. |
| FDBD01723 | Iopromide |
|
Contrast Media; X-Ray Contrast Media, Iodinated; Watersoluble, Nephrotropic, Low Osmolar X-Ray Contrast Media; | |
| FDBD02216 | phosglycin |
|
Insecticide | Insecticide |
| FDBD02351 | allidochlor |
|
Herbicide | Herbicide |
| FDBD02362 | diphenamid |
|
Herbicide | Herbicide |
| FDBD02811 | foramsulfuron |
|
Herbicide | Herbicide |
| FDBD02816 | nicosulfuron |
|
Herbicide | Herbicide |
12 ,
2
| FRAGNAME | PDBID | SIMILIRITY | XSCORE | SMILE | HAC |
|---|---|---|---|---|---|
| 1oth_ligand_1_3.mol2 | 1oth | 1 | -5.63 | CNC=O | 4 |
| 2h3e_ligand_1_2.mol2 | 2h3e | 1 | -5.63 | C(=O)NC | 4 |
| 4m3b_ligand_1_2.mol2 | 4m3b | 1 | -5.61 | CNC=O | 4 |
| 3i1y_ligand_1_3.mol2 | 3i1y | 1 | -5.59 | CNC=O | 4 |
| 4imz_ligand_frag_11.mol2 | 4imz | 1 | -5.59 | C(=O)N(C)C | 5 |
| 4inh_ligand_frag_9.mol2 | 4inh | 1 | -5.59 | C(=O)N(C)C | 5 |
| 5abh_ligand_frag_6.mol2 | 5abh | 1 | -5.59 | C(=O)NC | 4 |
| 4m3d_ligand_1_5.mol2 | 4m3d | 1 | -5.58 | C(=O)NC | 4 |
| 5abe_ligand_frag_0.mol2 | 5abe | 1 | -5.58 | O=CNC | 4 |
| 1qf1_ligand_1_5.mol2 | 1qf1 | 1 | -5.57 | C(=O)NC | 4 |
2387 ,
239
